Atara Biotherapeutics Inc

NASDAQ:ATRA   3:59:32 PM EDT
13.93
+0.69 (+5.21%)
Products, Strategic Combinations

Bayer, Atara Biotherapeutics Enter Pact For Car T-Cell Therapies

Published: 12/07/2020 04:11 GMT
Atara Biotherapeutics Inc (ATRA) - Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-targeted Car T-cell Therapies for Solid Tumors.
Atara Biotherapeutics Inc - Collaboration Will Focus on Off-the-shelf T-cell Immunotherapy Ata3271 for High Mesothelin-expressing Tumors.
Atara Biotherapeutics - Bayer to Enter Car T-cell Therapy Space, Expand Oncology Development.
Atara - to Receive Upfront Payment of $ 60 Million, and Up to Total of $610 Million for Development, Regulatory & Commercialization Milestones.
Atara Biotherapeutics Inc - Atara Will Lead Ind (investigational New Drug)-enabling Studies and Process Development for Ata3271.
Atara Biotherapeutics Inc - Bayer Will Be Responsible for Submitting the Ind and Subsequent Clinical Development and Commercialization.
Atara Biotherapeutics Inc - Atara to Receive Upfront Payment of USD 60 Million Plus Tiered Royalties Up to Low Double-digit Percentage of Net Sales.
Atara Biotherapeutics Inc - Collaboration Will Focus on Off--shelf T-cell Immunotherapy Ata3271 for High Mesothelin-expressing Tumors.
Atara Biotherapeutics - Atara to Also Provide Translational, Clinical Manufacturing Services to Be Reimbursed by Bayer.
Atara Biotherapeutics - for a Limited Period, Bayer Has Non-exclusive Right to Negotiate License for Additional Atara Car T Product Candidates.